Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing 99mTc-MAA and 90Y-microspheres radioembolization.

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Annals of Nuclear Medicine Pub Date : 2024-03-01 Epub Date: 2023-12-24 DOI:10.1007/s12149-023-01890-5
Nut Noipinit, Chanan Sukprakun, Punnarai Siricharoen, Kitiwat Khamwan
{"title":"Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-microspheres radioembolization.","authors":"Nut Noipinit, Chanan Sukprakun, Punnarai Siricharoen, Kitiwat Khamwan","doi":"10.1007/s12149-023-01890-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine the absorbed doses in the tumoral-liver and non-tumoral liver of hepatocellular carcinoma (HCC) patients undergoing radioembolization with Yttrium-90 (<sup>90</sup>Y) resin microspheres, and compared with those derived from <sup>99m</sup>Tc-MAA using the partition model.</p><p><strong>Methods: </strong>A total of 42 HCC patients (28 males and 14 females, mean age 65 ± 11.51 years) who received 45 treatment sessions with <sup>90</sup>Y-microspheres between 2016 and 2021 were included. Pre-treatment <sup>99m</sup>Tc-MAA and post-treatment <sup>90</sup>Y-bremsstrahlung SPECT/CT were acquired for each patient. Semi-automated segmentation of regions of interest (ROIs) was performed using MIM Encore software to determine the tumor-liver ratio (TLR) encompassing the liver volume, tumoral-liver, and lungs, and verified by both nuclear medicine physician and interventional radiologist. A partition dosimetry model was used to estimate the administered activity of <sup>90</sup>Y-microspheres and the absorbed doses to the tumoral-liver and non-tumoral liver. The student's paired t test and Bland-Altman plot were used for the statistical analysis.</p><p><strong>Results: </strong>The mean TLR values obtained from <sup>99m</sup>Tc-MAA SPECT/CT and <sup>90</sup>Y-bremsstrahlung SPECT/CT were 4.78 ± 3.51 and 2.73 ± 1.18, respectively. The mean planning administered activity of <sup>90</sup>Y-microspheres based on <sup>99m</sup>Tc-MAA SPECT/CT was 1.56 ± 0.80 GBq, while the implanted administered activity was 2.53 ± 1.23 GBq (p value < 0.001). The mean absorbed doses in the tumoral-liver estimated from <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-bremsstrahlung SPECT/CT were 127.44 ± 4.36 Gy and 135.98 ± 6.30 Gy, respectively. The corresponding mean absorbed doses in the non-tumoral liver were 34.61 ± 13.93 Gy and 55.04 ± 16.36 Gy.</p><p><strong>Conclusion: </strong>This study provides evidence that the administered activity of <sup>90</sup>Y-microspheres, as estimated from <sup>90</sup>Y-bremsstrahlung SPECT/CT, was significantly higher than that estimated from <sup>99m</sup>Tc-MAA SPECT/CT resulted in increased absorbed doses in both the tumoral-liver and non-tumoral liver. However, <sup>99m</sup>Tc-MAA SPECT/CT remains a valuable planning tool for predicting the distribution of <sup>90</sup>Y-microspheres in liver cancer treatment.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12149-023-01890-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aimed to determine the absorbed doses in the tumoral-liver and non-tumoral liver of hepatocellular carcinoma (HCC) patients undergoing radioembolization with Yttrium-90 (90Y) resin microspheres, and compared with those derived from 99mTc-MAA using the partition model.

Methods: A total of 42 HCC patients (28 males and 14 females, mean age 65 ± 11.51 years) who received 45 treatment sessions with 90Y-microspheres between 2016 and 2021 were included. Pre-treatment 99mTc-MAA and post-treatment 90Y-bremsstrahlung SPECT/CT were acquired for each patient. Semi-automated segmentation of regions of interest (ROIs) was performed using MIM Encore software to determine the tumor-liver ratio (TLR) encompassing the liver volume, tumoral-liver, and lungs, and verified by both nuclear medicine physician and interventional radiologist. A partition dosimetry model was used to estimate the administered activity of 90Y-microspheres and the absorbed doses to the tumoral-liver and non-tumoral liver. The student's paired t test and Bland-Altman plot were used for the statistical analysis.

Results: The mean TLR values obtained from 99mTc-MAA SPECT/CT and 90Y-bremsstrahlung SPECT/CT were 4.78 ± 3.51 and 2.73 ± 1.18, respectively. The mean planning administered activity of 90Y-microspheres based on 99mTc-MAA SPECT/CT was 1.56 ± 0.80 GBq, while the implanted administered activity was 2.53 ± 1.23 GBq (p value < 0.001). The mean absorbed doses in the tumoral-liver estimated from 99mTc-MAA and 90Y-bremsstrahlung SPECT/CT were 127.44 ± 4.36 Gy and 135.98 ± 6.30 Gy, respectively. The corresponding mean absorbed doses in the non-tumoral liver were 34.61 ± 13.93 Gy and 55.04 ± 16.36 Gy.

Conclusion: This study provides evidence that the administered activity of 90Y-microspheres, as estimated from 90Y-bremsstrahlung SPECT/CT, was significantly higher than that estimated from 99mTc-MAA SPECT/CT resulted in increased absorbed doses in both the tumoral-liver and non-tumoral liver. However, 99mTc-MAA SPECT/CT remains a valuable planning tool for predicting the distribution of 90Y-microspheres in liver cancer treatment.

比较接受99m锝-MAA和90Y-微球放射栓塞治疗的肝癌患者肿瘤肝脏和非肿瘤肝脏的吸收剂量。
目的:本研究旨在确定接受钇-90(90Y)树脂微球放射栓塞治疗的肝细胞癌(HCC)患者在肿瘤肝脏和非肿瘤肝脏中的吸收剂量,并利用分区模型与99m锝-MAA得出的吸收剂量进行比较:共纳入了 42 例 HCC 患者(男性 28 例,女性 14 例,平均年龄 65 ± 11.51 岁),他们在 2016 年至 2021 年期间接受了 45 次 90Y 微球治疗。每位患者均获得了治疗前的 99mTc-MAA 和治疗后的 90Y-轫致辐射 SPECT/CT。使用MIM Encore软件对感兴趣区(ROI)进行半自动分割,以确定包括肝脏体积、肿瘤-肝脏和肺部在内的肿瘤-肝脏比率(TLR),并由核医学医生和介入放射科医生共同验证。采用分区剂量测定模型估算 90Y 微球的给药活性以及肿瘤肝脏和非肿瘤肝脏的吸收剂量。统计分析采用了学生配对 t 检验和 Bland-Altman 图:99mTc-MAA SPECT/CT 和 90Y-轫致辐射 SPECT/CT 获得的平均 TLR 值分别为 4.78 ± 3.51 和 2.73 ± 1.18。基于 99mTc-MAA SPECT/CT 的 90Y 微球平均计划给药活性为 1.56 ± 0.80 GBq,而植入给药活性为 2.53 ± 1.23 GBq(p 值 99mTc-MAA 和 90Y 轫致辐射 SPECT/CT 分别为 127.44 ± 4.36 Gy 和 135.98 ± 6.30 Gy)。非肿瘤肝脏的相应平均吸收剂量分别为 34.61 ± 13.93 Gy 和 55.04 ± 16.36 Gy:本研究提供的证据表明,根据90Y-轫致辐射SPECT/CT估计,90Y-微球的给药活性明显高于99m锝-MAA SPECT/CT估计的活性,导致肿瘤肝脏和非肿瘤肝脏的吸收剂量增加。不过,99m锝-MAA SPECT/CT 仍是预测 90Y 微球在肝癌治疗中分布的重要计划工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信